This study is testing a medicine called MK-2214 to see if it can slow down brain changes in people with early Alzheimer's Disease (AD). AD is a disease that affects the brain and can make it hard to remember things, talk, and make decisions. MK-2214 is designed to slow down these changes.

Researchers want to know if MK-2214 can slow down the spread of tau, a protein that builds up in the brain and damages cells in AD. They will compare MK-2214 to a placebo, which looks like the medicine but doesn't have any active treatment. This helps researchers see the real effects of MK-2214. The study will also check how safe MK-2214 is and if people can tolerate it without problems.

To join the study, you need to have mild memory or thinking problems due to AD and have a study partner. However, you cannot join if you have other major brain diseases, recent seizures, or other serious health issues.

• Study Length: Participants will be involved for a specific duration, which the study team will explain.
• Visits Needed: You must be willing to undergo medical imaging tests like CT, PET, or MRI scans.
• Compensation: Details on any compensation will be provided by the study team.